Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Bispecific antibodies (BsAbs) represent a significant advancement in cancer therapy, particularly for lymphoid malignancies.
• Blinatumomab, the first approved BsAb, has transitioned from relapsed treatment to first-line therapy for B-cell acute lymphoblastic leukemia (B-ALL).

Purpose of the Study:

• To review the current landscape and future potential of bispecific antibodies in treating hematologic malignancies.
• To highlight the success of BsAbs in B-cell non-Hodgkin's lymphomas and multiple myeloma (MM).

Main Methods:

• Review of FDA-approved bispecific antibodies and their clinical applications.
• Analysis of ongoing and future clinical trials investigating BsAb combinations and earlier line treatments.

Main Results:

• Six additional BsAbs are FDA-approved for B-cell lymphomas and MM, demonstrating high response rates in refractory cases.
• Epcoritamab, glofitamab, and mosunetuzumab show promise for chemotherapy-free remissions in lymphoma.
• Teclistamab, talquetamab, and elranatamab achieve high complete remission (CR) rates in relapsed MM and are being studied in earlier settings.

Conclusions:

• BsAbs are highly effective in hematologic malignancies, offering new therapeutic options.
• Combination therapies and earlier line treatments with BsAbs hold significant promise for achieving durable remissions and potential cures.
• BsAbs are positioned to become frontline treatments for various hematologic cancers.